nav-left cat-right
cat-right

Epigenetic mechanisms in bone

Abstract Epigenetics refers to the study of mechanisms able to influence gene expression in a stable and potentially heritable manner without altering the DNA sequence. These mechanisms include posttranslational histone modifications, miRNA-mediated post-transcriptional regulation and DNA methylation. The accumulation of molecular errors over time resulting, at least partly, in the alteration of normal epigenetic patterns is...

New Genome-Editing Method

A new startup, backed with $43 million in venture investments, aims to develop treatments that could cure inherited diseases with a one-time fix based on a new method of genome editing. The method offers great precision in changing the DNA sequence of a genome and can potentially treat diseases that other forms of gene therapy cannot. The new method, to be commercialized by Editas Medicine, is based on a genome-editing system...

Biodatomics’ Open Source Approach

Maxim Mikheev is a co-founder and CEO of Biodatomics, gene informatics software companies. Mikheev is a molecular biologist, computer programmer, and aggressive entrepreneur. More uniquely, he is also an active member of the open source community, and BioDT, the platform his company unveiled two weeks ago at the ASHG conference in Boston, is open source from top to bottom. None of the roughly 400 distinct tools included in...

Chromatin proteins – new epigenetic drug tar...

A plethora of groundbreaking studies have demonstrated the importance of chromatin-associated proteins and post-translational modifications of histones, proteins and DNA (so-called epigenetic modifications) for transcriptional control and normal development. Disruption of epigenetic control is a frequent event in disease, and the first epigenetic-based therapies for cancer treatment have been approved. Nature ...

Developing a New Blood Test for Multiple Sclerosis

DioGenix formed an alliance with Fast Forward, a subsidiary of the National Multiple Sclerosis Society, to develop a novel blood test for multiple sclerosis (MS). Fast Forward will provide up to $500,000 as part of a Sponsored Research Agreement that will enable DioGenix to expand an ongoing clinical trial of its MS diagnostic, MSPrecise™, a next-generation sequencing assay that measures changes to the adaptive immune...

OGT Awarded $3.6M for Next-Generation Sequencing

Oxford Gene Technology (OGT) next-generation sequencing service team has been awarded two EU-funded clinical research grants worth €3 million (approximately $3.6 million). OGT will be providing genomic analysis and commercialization services for two international studies, EUCLIDS and PATHSEEK. EUCLIDS (EU Life-threatening Infectious Disease Study), is a five-year, large-scale study to identify genomic variants that...
Page 3 of 1112345...10...Last »